AR115936A1 - Compuestos útiles en terapia del vih - Google Patents
Compuestos útiles en terapia del vihInfo
- Publication number
- AR115936A1 AR115936A1 ARP190102256A ARP190102256A AR115936A1 AR 115936 A1 AR115936 A1 AR 115936A1 AR P190102256 A ARP190102256 A AR P190102256A AR P190102256 A ARP190102256 A AR P190102256A AR 115936 A1 AR115936 A1 AR 115936A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- useful compounds
- alkyl
- hiv therapy
- alkynyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), en la que R¹ es: un compuesto de la fórmula (2); X se selecciona entre el grupo que consiste en NH₂, F y CI; R² es -C(=O)-R⁴ en el que R⁴ se selecciona entre el grupo que consiste en alquilo C₁₋₂₅, alquenilo C₂₋₂₅, alquinilo C₂₋₂₅ y haloalquilo C₁₋₁₀; en la que cada uno de R⁴ puede estar opcionalmente sustituido con alquilo C₁₋₆, Cl, F, oxo, o alcoxi C₁₋₆; R³ se selecciona entre el grupo que consiste en H y -(C=O)-O-R⁵, en la que R⁵ se selecciona entre el grupo que consiste en alquilo C₁₋₁₀, alquenilo C₂₋₁₀ y alquinilo C₂₋₁₀; y R⁶ y R⁷ se seleccionan independientemente entre el grupo que consiste en H- y C(=O)-OR⁸, en la que R⁸ es alquilo C₁₋₁₀; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862716494P | 2018-08-09 | 2018-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115936A1 true AR115936A1 (es) | 2021-03-17 |
Family
ID=68072882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102256A AR115936A1 (es) | 2018-08-09 | 2019-08-08 | Compuestos útiles en terapia del vih |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220117993A1 (es) |
| EP (1) | EP3833437A1 (es) |
| JP (1) | JP2021534112A (es) |
| KR (1) | KR20210044806A (es) |
| CN (1) | CN112789085A (es) |
| AR (1) | AR115936A1 (es) |
| AU (1) | AU2019317810A1 (es) |
| BR (1) | BR112021002169A2 (es) |
| CA (1) | CA3108635A1 (es) |
| CL (1) | CL2021000329A1 (es) |
| IL (1) | IL280660A (es) |
| MA (1) | MA53280A (es) |
| MX (1) | MX2021001612A (es) |
| TW (1) | TW202023650A (es) |
| WO (1) | WO2020031131A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020211600A1 (en) | 2019-01-25 | 2021-07-22 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| MA55200A (fr) | 2019-03-06 | 2022-01-12 | Glaxosmithkline Ip No 2 Ltd | Composés utiles dans la thérapie du vih |
| AU2020320876B2 (en) | 2019-07-27 | 2025-09-25 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| US20220259252A1 (en) * | 2019-08-08 | 2022-08-18 | Glaxosmithkline Intellectual Property (No.2) Limited | 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy |
| EP4121437A1 (en) * | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2022159877A1 (en) | 2021-01-25 | 2022-07-28 | Brii Biosciences, Inc. | Combination therapy for hiv with adenosine derivative and capsid inhibitors |
| CA3202049A1 (en) * | 2021-01-25 | 2022-07-28 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| CN1533390A (zh) | 2001-03-19 | 2004-09-29 | СҰҩƷ��ҵ��ʽ���� | 包含三氮杂螺[5.5]十一烷衍生物作为活性成分的药物组合物 |
| CA2502109C (en) * | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| CN101784557A (zh) * | 2007-05-14 | 2010-07-21 | Rfs制药公司 | 用于治疗病毒感染的叠氮基嘌呤核苷 |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| WO2017027434A1 (en) * | 2015-08-10 | 2017-02-16 | Merck Sharp & Dohme Corp. | Antiviral beta-amino acid ester phosphodiamide compounds |
| US20190185508A1 (en) * | 2017-12-15 | 2019-06-20 | Merck Sharp & Dohme Corp. | Deuterated nucleoside reverse transcriptase inhibitors |
-
2019
- 2019-08-08 WO PCT/IB2019/056761 patent/WO2020031131A1/en not_active Ceased
- 2019-08-08 TW TW108128258A patent/TW202023650A/zh unknown
- 2019-08-08 MX MX2021001612A patent/MX2021001612A/es unknown
- 2019-08-08 AU AU2019317810A patent/AU2019317810A1/en not_active Abandoned
- 2019-08-08 US US17/266,675 patent/US20220117993A1/en not_active Abandoned
- 2019-08-08 CA CA3108635A patent/CA3108635A1/en not_active Abandoned
- 2019-08-08 AR ARP190102256A patent/AR115936A1/es not_active Application Discontinuation
- 2019-08-08 EP EP19779131.2A patent/EP3833437A1/en not_active Withdrawn
- 2019-08-08 CN CN201980066756.7A patent/CN112789085A/zh active Pending
- 2019-08-08 KR KR1020217006489A patent/KR20210044806A/ko not_active Withdrawn
- 2019-08-08 BR BR112021002169-8A patent/BR112021002169A2/pt not_active Application Discontinuation
- 2019-08-08 MA MA053280A patent/MA53280A/fr unknown
- 2019-08-08 JP JP2021506694A patent/JP2021534112A/ja active Pending
-
2021
- 2021-02-04 IL IL280660A patent/IL280660A/en unknown
- 2021-02-08 CL CL2021000329A patent/CL2021000329A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020031131A1 (en) | 2020-02-13 |
| EP3833437A1 (en) | 2021-06-16 |
| AU2019317810A1 (en) | 2021-02-25 |
| IL280660A (en) | 2021-03-25 |
| MX2021001612A (es) | 2021-05-13 |
| CN112789085A (zh) | 2021-05-11 |
| US20220117993A1 (en) | 2022-04-21 |
| CL2021000329A1 (es) | 2021-09-03 |
| JP2021534112A (ja) | 2021-12-09 |
| CA3108635A1 (en) | 2020-02-13 |
| BR112021002169A2 (pt) | 2021-05-04 |
| KR20210044806A (ko) | 2021-04-23 |
| TW202023650A (zh) | 2020-07-01 |
| MA53280A (fr) | 2021-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115936A1 (es) | Compuestos útiles en terapia del vih | |
| AR110405A1 (es) | Compuestos | |
| AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| AR107955A1 (es) | Derivados de piridino- / pirimidino-piridina, con actividad herbicida | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR098100A1 (es) | Composiciones plaguicidas y los métodos relacionados | |
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR100702A1 (es) | Compuestos inhibidores de quinasa de unión tank | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR106100A1 (es) | Compuestos bicíclicos como inhibidores duales atx / ca | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR098104A1 (es) | Composiciones pesticidas y métodos relacionados | |
| AR125908A1 (es) | Nueva piridina sustituida | |
| AR117037A1 (es) | Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias | |
| AR109108A1 (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 | |
| AR108864A1 (es) | Agentes antibacterianos | |
| AR119074A1 (es) | Ácidos 1-fenil-5-azinilpirazolil-3-oxialquilícos y su uso para combatir el crecimiento no deseado de plantas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |